Delcath Receives CRL from FDA for Melbleztm Kit NDA

Delcath Systems, Inc. (NASDAQ: DCTH ) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) received September 12, 2013 regarding the New Drug Application (NDA) for Delcath's MelblezTM Kit (Melblez (melphalan) for Injection for use with the Delcath Hepatic Delivery System)